Peter Simon

Credit Suisse Securities (USA) LLC (Credit Suisse Securities USA) is the broker/dealer division of Credit Suisse Securities (USA) LLC, an investment banking company headquartered in New York City. The firm was founded in 1998 and is a wholly owned subsidiary of Credit Suisse (USA), Inc., ultimately owned by Credit Suisse Group AG (SWX: CSGN) in Switzerland. Credit Suisse Securities USA offers a suite of equities, solutions and credit products and services which includes global securities sales, trading and execution, prime brokerage and comprehensive investment research. Their clients include financial institutions, corporations, governments, institutional investors, such as pension funds and hedge funds, and private individuals around the world.

PricewaterhouseCoopers LLC provides assurance, tax and advisory services. Its services include audit and assurance, consulting, deals, human resources, legal, tax, and family business. The firm also offers accountability, risk management, structuring, mergers and acquisitions, and performance and process improvement. The company was founded in 1998 and is headquartered in Buffalo, NY.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Pasteur Foundation operates as a research center. The private company is based in New York, NY.

Drillgreat Ltd. operated as a holding company. It engages in retails fashion clothing. The company was founded by Peter Michael Simon on June 26, 2007 and was headquartered in London, the United Kingdom.

Monsoon Holdings Ltd. operates as an investment holding company with interest in the retail of accessories. The company was founded on February 13, 1975 and is headquartered in London, the United Kingdom.

Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY.